en
svPress releases
Regulatory press release 2022-08-05
Interim Report Second Quarter 2022
Regulatory press release 2022-06-17
Dasynoc granted Orphan Drug Designation in the US for the treatment of chronic myeloid leukemia
Regulatory press release 2022-06-15
Xspray Pharma appoints Thomas Walz as Chief Medical Officer
Press release 2022-06-09
Xspray Pharma’s long-term incentive program LTI 2022 fully subscribed
Regulatory press release 2022-05-19
Bulletin from the 2022 Annual General Meeting of Xspray Pharma AB (publ)
Press release 2022-05-06
Xspray Pharma – Capital Markets Day Invitation
Regulatory press release 2022-05-06
An eventful quarter sets the agenda for an intense 2022
Press release 2022-04-19
The Nomination Committee’s proposal for the Board of Directors of Xspray Pharma AB
Regulatory press release 2022-04-19
Notice of annual general meeting of Xspray Pharma AB (publ)
Regulatory press release 2022-03-25
Xspray Pharma publishes its annual report for 2021
Subscribe
IR contact
Christina Malmberg Hägerstrand, SVP Communications & IR